My Treatment Approach: Optimizing Care for Relapsed / Refractory Multiple Myeloma: Translating Evidence to Clinical Practice - Episode 9

Challenges of Treatment Sequencing in Heavily Pre-Treated R/R MM: Expert Insights

,

The experts in relapsed/refractory multiple myeloma care outline their treatment sequencing strategies for patients who have already received T-cell engaging therapies.

EP. 1: Clinical Scenario I: 68-yr Old Man with Early Relapse MM
EP. 2: Clinical Insights on Next Treatment Approach Steps
EP. 3: Real Life Clinical Practice Use of Selinexor: Dosing Strategies, Supportive Care, and Strategies to Incorporate into Novel Selinexor-Based Regimens
EP. 4: Expert Perspectives: Navigating the Evolving Treatment Landscape in Early Relapse MM
EP. 5: Overview of CAR T-cell Therapy Options in R/R MM
EP. 6: Expert Perspectives: Selinexor Role in the Changing Treatment Landscape in MM and Key Takeaways
EP. 7: Patient Profile: 53-Year-Old Man with Heavily Pre-Treated MM including T-cell Directed Therapy
EP. 8: Clinical Insights on the Patient Presentation & Treatment Course
Now Viewing
EP. 9: Challenges of Treatment Sequencing in Heavily Pre-Treated R/R MM: Expert Insights
EP. 10: Potential Novel Lab Monitoring & Key Takeaways for Heavily Pre-Treated R/R MM

Video content above is prompted by the following:

  • What is your treatment sequencing approach for those who already received T-cell engaging therapies?
  • What are some treatment options for those who have already received T-cell directed therapies in the R/R MM setting?

Related Content:

My Treatment Approach: Optimizing Care for Relapsed / Refractory Multiple Myeloma: Translating Evidence to Clinical PracticeThe University of Texas MD Anderson Cancer CenterWinship Cancer Institute of Emory UniversityMultiple MyelomaInsights
FDA Approves Isatuximab Plus VRd for Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
Subcutaneous Daratumumab Quadruplet Approaches EU Approval for Newly Diagnosed Myeloma
Clinical Scenario: Locally Recurrent NPC